Funding for this research was provided by:
O. Hardiman is funded by the Health Research Board Clinician Scientist Programme and Science Foundation Ireland
The Thierry Latran Foundation (ALSIBD) and the ALS Association (2284) support R.L. McLaughlin.
This project was supported by the Netherlands Organisation for Health Research and Development (Vici scheme to L.H. van den Berg).
Text and Data Mining valid from 2019-04-11
Received: 28 August 2018
Accepted: 25 March 2019
First Online: 11 April 2019
: L.H. van den Berg serves on scientific advisory boards for the Prinses Beatrix Spierfonds, Thierry Latran Foundation, Biogen and Cytokinetics; and serves on the editorial board of Amyotrophic Lateral Sclerosis And Frontotemporal Degeneration and The Journal of Neurology, Neurosurgery, and Psychiatry. J.H. Veldink reports that his institute received consultancy fees from Vertex Pharmaceuticals outside the submitted work. O. Hardiman has received speaking honoraria from Novarits, Biogen Idec, Sanofi Aventis and Merck-Serono, has been a member of advisory panels for Biogen Idec, Allergen, Ono Pharmaceuticals, Novartis, Cytokinetics and Sanofi Aventis and serves as Editor-in-Chief of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Other authors have no reported conflicts of interest.